Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery
CC-90010-GBM-002
Phase 1 other active
Quick answer
Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery for Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection is a Phase 1 program (other) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Celgene Europe Limited
- Indication
- Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection
- Phase
- Phase 1
- Modality
- other
- Status
- active